As with the Top Pharma list, currency exchange flux makes it difficult to compare all of our Biopharmas, but U.S. dollar-reporting companies — Amgen, Baxter, Biogen, Allergan, Alexion and Dendreon — showed cumulative growth of 7% in 2011, combining for $29.0 billion in revenues. That’s up from 4% in 2010 (swapping Genzyme for Dendreon).
Note: a company qualifies as a “Biopharma” if it makes at least 50% of its drug revenues from selling biologics and vaccines. Small-molecule companies need not apply.
—Gil Y. Roth
Editor
Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks
The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com)
Pipeline information compiled by Kristin Brooks
Revenue information compiled by Gil Roth
Photo of Avastin packaging courtesy of Roche
Top 10 Biopharma Companies
based on 2011 biopharma revenues
1 |
$37,110 |
|
2 |
$15,582 |
|
3 |
$12,400 |
|
4 |
$8,243 |
|
5 |
$6,053 |
|
6 |
$4,833 |
|
7 |
$4,145 |
|
8 |
$1,595 |
|
9 |
$783 |
|
10 |
$214 |
2011 R&D Expenditures
1 | Roche |
$9,148 |
2 |
Amgen |
$3,167 |
3 |
Novo Nordisk |
$1,799 |
4 |
Merck Serono |
$1,706 |
5 |
Biogen Idec |
$1,220 |
6 |
Baxter |
$946 |
7 |
Allergan |
$903 |
8 |
CSL Ltd. |
$322 |
9 |
Alexion Pharma |
$137 |
10 |
Dendreon |
$74 |
Note: In all Top Company profiles, dollar amounts are in millions.